版本:
中国

BRIEF-XBiotech announces top-line results for 514G3 antibody therapy in serious staphylococcus aureus infections

April 3 XBiotech Inc

* XBiotech announces top-line results for 514G3 antibody therapy in serious staphylococcus aureus infections

* XBiotech Inc - no drug-related adverse events were observed at any of dose escalation levels for 514G3 antibody therapy

* XBiotech Inc - total of 28 SAES in 15 patients were reported during study period including 4 deaths

* XBiotech Inc - "although deaths observed in treatment arm of study did not appear to be drug-related, this will warrant careful evaluation in larger studies"

* XBiotech Inc - four deaths occurred in treatment arm versus none in placebo group in study Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐